Form 10-Q 4Front Ventures Corp. For: Jun 30
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered | ||
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
Non-accelerated filer |
☒ |
Smaller reporting company |
||||
Emerging growth company |
Page |
||||||
PART I. |
||||||
Item 1. |
||||||
1 |
||||||
2 |
||||||
3 |
||||||
5 |
||||||
6 |
||||||
Item 2. |
29 |
|||||
Item 3. |
38 |
|||||
Item 4. |
38 |
|||||
PART II. |
||||||
Item 1. |
40 |
|||||
Item 1A. |
40 |
|||||
Item 2. |
41 |
|||||
Item 3. |
41 |
|||||
Item 4. |
41 |
|||||
Item 5. |
41 |
|||||
Item 6. |
42 |
|||||
43 |
June 30, 2022 |
December 31, 2021 |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash |
$ | $ | ||||||
Accounts receivable, net |
||||||||
Other receivables |
||||||||
Current portion of lease receivables |
||||||||
Inventory |
||||||||
Current portion of notes receivable |
||||||||
Prepaid expenses |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
Property, plant, and equipment, net |
||||||||
Lease receivables |
||||||||
Intangible assets, net |
||||||||
Goodwill |
||||||||
Right-of-use |
||||||||
Deposits |
||||||||
|
|
|
|
|||||
TOTAL ASSETS |
$ | $ | ||||||
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
LIABILITIES |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses and other current liabilities |
||||||||
Taxes payable |
||||||||
Derivative liability |
||||||||
Current portion of contract liabilities |
||||||||
Current portion of convertible notes |
||||||||
Current portion of lease liability |
||||||||
Current portion of notes payable and accrued interest |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
Convertible notes |
||||||||
Notes payable and accrued interest from related party |
||||||||
Long term notes payable |
||||||||
Long term accounts payable |
||||||||
Contract liabilities |
||||||||
Contingent consideration payable |
||||||||
Construction finance liability |
||||||||
Deferred tax liability |
||||||||
Lease liability |
||||||||
|
|
|
|
|||||
TOTAL LIABILITIES |
||||||||
|
|
|
|
|||||
SHAREHOLDERS’ EQUITY |
||||||||
Equity attributable to 4Front Ventures Corp. |
||||||||
Additional paid-in capital |
||||||||
Deficit |
( |
) | ( |
) | ||||
Non-controlling interest |
||||||||
|
|
|
|
|||||
TOTAL SHAREHOLDERS’ EQUITY |
||||||||
|
|
|
|
|||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ | $ | ||||||
|
|
|
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
REVENUE |
||||||||||||||||
Revenue from sale of goods |
$ | $ | $ | $ | ||||||||||||
Real estate income |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total revenues |
||||||||||||||||
Cost of goods sold |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross profit |
||||||||||||||||
OPERATING EXPENSES |
||||||||||||||||
Selling and marketing expenses |
||||||||||||||||
General and administrative expenses |
||||||||||||||||
Depreciation and amortization |
||||||||||||||||
Transaction and restructuring related expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity based compensation |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expenses |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
(Loss) Income from operations |
( |
) | ( |
) | ||||||||||||
Other income (expense) |
||||||||||||||||
Interest income |
||||||||||||||||
Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Amortization of loan discount upon conversion of debt to equity |
( |
) | ||||||||||||||
Change in fair value of derivative liability |
( |
) | ( |
) | ||||||||||||
Change in contingent consideration payable |
||||||||||||||||
Loss on lease termination |
( |
) | ( |
) | ||||||||||||
Other |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total other income (expense), net |
( |
) | ( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss before income taxes |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Income tax expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Net loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Net income attributable to non-controlling interest |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss attributable to shareholders |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted loss per share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Weighted average number of shares outstanding, basic and diluted |
Share Capital |
||||||||||||||||||||||||||||
Shares |
Amount |
Additional Paid-In Capital |
Deficit |
Total 4Front Ventures Corp. Shareholders’ Equity |
Non- Controlling Interest |
Total Shareholders’ Equity |
||||||||||||||||||||||
Balance, December 31, 2021 |
$ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||
Shares issued for NECC pursuant to acquisition |
— | — | — | |||||||||||||||||||||||||
Share-based compensation |
— | — | — | — | ||||||||||||||||||||||||
Conversion of notes to equity |
— | — | — | |||||||||||||||||||||||||
Shares issued with exercise of warrants |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, March 31, 2022 |
$ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Shares issued for Island pursuant to acquisition |
— | — | — | |||||||||||||||||||||||||
Warrants issued for Island pursuant to acquisition |
— | — | — | — | ||||||||||||||||||||||||
Share-based compensation |
— | — | — | — | ||||||||||||||||||||||||
Shares issued with exercise of stock options |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, June 30, 2022 |
$ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Capital |
||||||||||||||||||||||||||||
Shares |
Amount |
Additional Paid-In Capital |
Deficit |
Total 4Front Ventures Corp. Shareholders’ Equity |
Non- Controlling Interest |
Total Shareholders’ Equity |
||||||||||||||||||||||
Balance, December 31, 2020 |
$ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Shares issued for Pure Ratios earnout |
— | — | — | |||||||||||||||||||||||||
Share-based compensation |
— | — | — | — | ||||||||||||||||||||||||
Conversion of notes to equity |
— | — | — | |||||||||||||||||||||||||
Shares issued with exercise of stock options |
— | — | — | |||||||||||||||||||||||||
Shares issued with exercise of warrants |
— | — | — | |||||||||||||||||||||||||
Return of treasury shares |
( |
) | — | — | — | — | — | — | ||||||||||||||||||||
Net loss |
— | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, March 31, 2021 |
$ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Shares issued for Om of Medicine earnout |
— | — | — | |||||||||||||||||||||||||
Share-based compensation |
— | — | — | — | ||||||||||||||||||||||||
Conversion of notes to equity |
— | — | — | |||||||||||||||||||||||||
Shares issued with exercise of stock options |
— | — | — | |||||||||||||||||||||||||
Shares issued with exercise of warrants |
— | — | — | |||||||||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, June 30, 2021 |
$ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
||||||||
2022 |
2021 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used by operating activities |
||||||||
Depreciation and amortization |
||||||||
Equity based compensation |
||||||||
Change in fair value of derivative liability |
( |
) | ||||||
Change in fair value of contingent consideration |
( |
) | ||||||
Amortization of right-of-use |
||||||||
Accretion of lease liability |
( |
) | ||||||
Write-off of fixed asset from terminated lease |
||||||||
Accretion of contingent consideration |
||||||||
Accretion of convertible debenture and interest |
||||||||
Accrued interest on notes payable |
||||||||
Interest accrued - lease receivable |
||||||||
Deferred taxes |
( |
) | ||||||
Amortization of loan discount upon conversion of debt to equity |
||||||||
Changes in operating assets and liabilities |
( |
) | ||||||
|
|
|
|
|||||
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES |
( |
) | ||||||
|
|
|
|
|||||
CASH FLOWS FROM INVESTING ACTIVITIES |
||||||||
Payment for NECC business combination, net of cash acquired |
( |
) | ||||||
Cash acquired as part of Island business combination |
||||||||
Notes receivable repayments |
||||||||
Sale of dispensaries and interests in cannabis licenses |
||||||||
Purchases of property and equipment |
( |
) | ( |
) | ||||
|
|
|
|
|||||
NET CASH USED IN INVESTING ACTIVITIES |
( |
) | ( |
) | ||||
|
|
|
|
|||||
CASH FLOWS FROM FINANCING ACTIVITIES |
||||||||
Payment of contingent consideration |
( |
) | ( |
) | ||||
Proceeds from issuance of construction financing liability |
||||||||
Proceeds from the exercise of warrants |
||||||||
Proceeds from the exercise of stock options |
||||||||
Repayment of notes payable |
( |
) | ( |
) | ||||
|
|
|
|
|||||
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES |
( |
) | ||||||
|
|
|
|
|||||
NET DECREASE IN CASH |
( |
) | ( |
) | ||||
CASH, BEGINNING OF QUARTER |
||||||||
|
|
|
|
|||||
CASH, END OF QUARTER |
$ | $ | ||||||
|
|
|
|
(a) |
Critical accounting estimates and judgments |
(b) |
Recent Accounting Pronouncements |
i. | In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows. |
ii. | In May 2021, the FASB issued ASU 2021-04, “Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (Subtopic 815-40)”. ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Adoption of this standard did not materially impact the Company’s consolidated financial position, results of operations or cash flows. |
iii. | In October 2021, the FASB issued ASU 2021-08, “Business Combinations—Accounting for Contract Assets and Contract Liabilities (Topic 805)”. The amendments in this update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination by requiring that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. As a result of the amendments made by the ASU, it is expected than an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur on or after the date of initial application. The Company has elected to early adopt this standard as of January 1, 2022. The adoption of the standard had an impact on the valuation of Island deferred revenue contracts upon the acquisition date. The Company recognized the contract liabilities acquired consistent with the previous accounting treatment at the acquired entity. This standard did not have an impact on the NECC acquisition entered into on January 28, 2022. |
i. | In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurements—Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820)”. ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements. |
June 30, 2022 |
December 31, 2021 |
|||||||
Raw materials - unharvested cannabis |
$ | $ | ||||||
Raw materials - harvested and purchased cannabis |
||||||||
Packaging and other non-finished goods |
||||||||
Work in process - manufactured and purchased extracts |
||||||||
Finished goods |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
June 30, 2022 |
December 31, 2021 |
|||||||
Land |
$ | $ | ||||||
Buildings & improvements |
||||||||
Construction in process |
||||||||
Furniture, equipment & other |
||||||||
Leasehold improvements |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
Less: accumulated depreciation |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total property, plant, and equipment, net |
$ | $ | ||||||
|
|
|
|
Licenses |
Customer Relationships |
Non-Competition Agreements |
Know-How |
Tradenames and Trademarks |
Total |
|||||||||||||||||||
Balance, December 31, 2020 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||
Amortization expense |
— | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||
Balance, December 31, 2021 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||
NECC merger and 29 Everett acquisition (Note 7) |
— | — | — | — | ||||||||||||||||||||
Island merger (Note 7) |
— | — | — | |||||||||||||||||||||
Amortization expense |
— | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||
Balance, June 30, 2022 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||
Balance, December 31, 2020 |
$ |
|||
Balance, December 31, 2021 |
$ |
|||
NECC merger and 29 Everett acquisition (Note 7) |
||||
Island merger (Note 7) |
||||
Balance, June 30, 2022 |
$ |
|||
Cash consideration |
$ | |||
Seller note |
||||
Equity consideration - common stock |
||||
|
|
|||
Total Purchase Price |
$ | |||
|
|
Description |
Fair value |
|||
Assets acquired: |
||||
Cash |
$ | |||
Inventory |
||||
Property, plant, and equipment |
||||
Intangible asset - licenses |
||||
|
|
|||
Total assets acquired |
$ | |||
|
|
|||
Liabilities assumed: |
||||
Accounts payable |
||||
|
|
|||
Total liabilities assumed |
$ | |||
|
|
|||
Estimated fair value of net assets acquired |
$ | |||
|
|
|||
Estimated Goodwill |
$ | |||
|
|
Seller note |
$ | |||
Equity consideration - common stock |
||||
Equity consideration - warrants |
||||
|
|
|||
Total Purchase Price |
$ |
Description |
Fair value |
|||
Assets acquired: |
||||
Cash |
$ | |||
Accounts receivable |
||||
Inventory |
||||
Prepaid expenses and other current assets |
||||
Property and equipment, net |
||||
Operating lease - right of use asset |
||||
Intangible assets |
||||
|
|
|||
Total assets acquired |
$ | |||
|
|
|||
Liabilities assumed: |
||||
Accounts payable |
$ | |||
Accrued expenses and other liabilities |
||||
Contract liabilities |
||||
Lease liabilities |
||||
Notes payable |
||||
Total liabilities assumed |
$ |
|||
|
|
|||
Estimated fair value of net assets acquired |
$ | |||
|
|
|||
Estimated Goodwill |
$ | |||
|
|
For the For the Three Months Ended June 30, |
||||||||||||||||
2022 |
2021 |
|||||||||||||||
Reported |
Proforma |
Reported |
Proforma |
|||||||||||||
Revenues |
$ | $ | $ | $ | ||||||||||||
(Loss) income from operations |
( |
) | ( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted earning (loss) per share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) |
For the For the Six Months Ended June 30, |
||||||||||||||||
2022 |
2021 |
|||||||||||||||
Reported |
Proforma |
Reported |
Proforma |
|||||||||||||
Revenues |
$ | $ | $ | $ | ||||||||||||
(Loss) income from operations |
( |
) | ( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted earning (loss) per share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) |
Classification - Consolidated Balance Sheet |
June 30, 2022 |
December 31, 2021 |
||||||||
Assets |
||||||||||
Operating lease assets |
Operating Lease Assets |
$ | $ | |||||||
Liabilities |
||||||||||
Current |
||||||||||
Operating |
Current portion of operating lease liabilities |
|||||||||
Noncurrent |
||||||||||
Operating |
Operating lease liabilities |
|||||||||
|
|
|
|
|||||||
Total lease liabilities |
$ | $ | ||||||||
|
|
|
|
Operating Leases |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
2027 |
||||
2028 and Thereafter |
||||
|
|
|||
Total undiscounted cash flows |
$ | |||
Less discounting |
( |
) | ||
|
|
|||
Total lease payments |
$ | |||
|
|
June 30, 2022 |
December 31, 2021 |
|||||||
Balance, beginning of the year |
$ | $ | ||||||
Interest |
||||||||
Lease payments received |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Balance, end of the period |
$ |
$ | ||||||
Less current portion |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Long-term lease receivables |
$ | $ | ||||||
|
|
|
|
Operating Leases |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total minimum lease payments |
||||
Effect of discounting |
( |
) | ||
Present value of minimum lease payments |
||||
Present value of residual value of leased property |
||||
|
|
|||
Total lease receivable |
||||
Current portion lease receivable |
( |
) | ||
|
|
|||
Long-term lease receivable |
$ | |||
|
|
LI Lending, LLC |
May 2020 Convertible Notes |
2022 Island Global Holdings Related Party Notes |
May 2020 Convertible Notes (Swap) |
October 2021 Convertible Note |
Other Loans |
Total |
||||||||||||||||||||||
Balance, December 31, 2020 |
$ | $ | $ | $ | $ | — | $ | $ | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Loans advanced, net |
— | |||||||||||||||||||||||||||
Loan payments |
( |
) | — | — | ( |
) | ( |
) | ||||||||||||||||||||
Converted to equity |
— | ( |
) | ( |
) | — | ( |
) | ||||||||||||||||||||
Accrued interest |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, December 31, 2021 |
$ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Loans advanced, net |
— | — | — | |||||||||||||||||||||||||
Loan payments |
( |
) | — | — | ( |
) | ( |
) | ||||||||||||||||||||
Converted to equity |
— | — | ( |
) | ( |
) | ||||||||||||||||||||||
Accrued interest |
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, June 30, 2022 |
$ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
Less current portion |
— | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Long-term portion |
$ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other |
Subsidiary |
Terms |
June 30, 2022 |
December 31, 2021 |
|||||||
Healthy Pharms Inc. | Unsecured convertible note, due November 18 |
$ | $ | |||||||
Healthy Pharms Inc. | ||||||||||
Island Global | ||||||||||
NECC | ||||||||||
Om of Medicine, LLC | ||||||||||
Arkansas Entities | ||||||||||
Equipment Loans | ||||||||||
Other | ||||||||||
Total Notes Payable and Convertible Notes |
$ | $ | ||||||||
(1) | In November 2021, the unsecured promissory note was modified to be due and payable in full on or before ASC 470 |
(2) |
In July 2022, the promissory note was modified, whereby |
(3) |
In April 2022, the Company entered into a seller note payable to pay the outstanding balance due resulting from the 2021 Om earnout in connection with prior period contingent considerations. The note bore |
June 30, 2022 |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
Total minimum payments |
||||
Effect of discounting |
( |
) | ||
Present value of minimum payments |
||||
Less current portion |
( |
) | ||
Long-term portion |
$ | |||
Class A Subordinate Voting Shares |
Class C Multiple Voting Shares |
Total |
||||||||||
Balance, December 31, 2020 |
||||||||||||
Share capital issuances |
||||||||||||
Balance, December 31, 2021 |
||||||||||||
Share capital issuances |
||||||||||||
Balance, June 30, 2022 |
||||||||||||
Series |
Shares outstanding as of June 30, 2022 |
As converted to SVS Shares |
||||||
Class A - Subordinate Voting Shares |
||||||||
Class C - Multiple Voting Shares |
||||||||
Series |
Number of warrants |
Weight-average exercise price |
||||||
Balance, December 31, 2021 |
$ | |||||||
Issued |
||||||||
Exercised |
( |
) | ||||||
|
|
|
|
|||||
Balance, June 30, 2022 |
$ | |||||||
|
|
|
|
Warrants Outstanding |
Exercise Price |
Expiry Date |
||||||
|
C$ | |
* | |||||
|
C$ | |
* | |||||
|
$ | * | ||||||
|
$ | * | ||||||
|
$ | |||||||
|
C$ | |
* | |||||
|
C$ | |
* | |||||
|
||||||||
|
||||||||
|
* | Represents warrants that are exercisable as of June 30, 2022. |
Grant Date |
Strike Price in CAD$ |
Outstanding Options |
Exercisable Options |
Life Remaining (years) |
||||||||||||
July 31, 2019 |
||||||||||||||||
July 31, 2019 |
||||||||||||||||
July 31, 2019 |
||||||||||||||||
July 31, 2019 |
||||||||||||||||
July 31, 2019 |
||||||||||||||||
August 22, 2019 |
||||||||||||||||
August 22, 2019 |
||||||||||||||||
November 1, 2019 |
||||||||||||||||
February 3, 2020 |
||||||||||||||||
June 8, 2020 |
||||||||||||||||
July 31, 2020 |
||||||||||||||||
September 15, 2020 |
||||||||||||||||
October 2, 2020 |
||||||||||||||||
November 24, 2020 |
||||||||||||||||
December 2, 2020 |
||||||||||||||||
December 21, 2020 |
||||||||||||||||
March 18, 2021 |
||||||||||||||||
April 2, 2021 |
||||||||||||||||
April 21, 2021 |
||||||||||||||||
June 23, 2021 |
||||||||||||||||
November 11, 2021 |
||||||||||||||||
January 25, 2022 |
||||||||||||||||
February 1, 2022 |
||||||||||||||||
February 17, 2022 |
||||||||||||||||
March 1, 2022 |
||||||||||||||||
April 27, 2022 |
||||||||||||||||
June 17, 2022 |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Number of Options |
Weighted Average Price CAD$ |
Weighted Average Years |
||||||||||
Balance December 31, 2020 |
||||||||||||
Granted |
||||||||||||
Exercised |
( |
) | — | |||||||||
Forfeited/ Expired |
( |
) | — | |||||||||
|
|
|
|
|
|
|||||||
Balance December 31, 2021 |
||||||||||||
Granted |
||||||||||||
Exercised |
( |
) | — | |||||||||
Forfeited/ Expired |
( |
) | — | |||||||||
|
|
|
|
|
|
|||||||
Balance June 30, 2022 |
2022 |
2021 |
|||||||
Risk-Free Interest Rate |
% | % to | ||||||
Expected Life (years) |
||||||||
Expected Annualized Volatility |
% | % to | ||||||
Forfeiture rate |
% | % | ||||||
Expected Dividend Yield |
% | % |
Om of Medicine |
||||
Balance, December 31, 2021 |
$ | |||
Changes in fair value |
( |
) | ||
Balance, June 30, 2022 |
||||
Less: current portion |
— | |||
Long-term portion |
$ |
Level 1 |
Quoted prices (unadjusted) in active markets for identical assets or liabilities; | |
Level 2 |
Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and | |
Level 3 |
Inputs for the asset or liability that are not based on observable market data (unobservable inputs). |
Fair value at June 30, 2022 |
||||||||||||||||
Total |
Level 1 |
Level 2 |
Level 3 |
|||||||||||||
Liabilities: |
||||||||||||||||
Derivative liability |
$ | $ | $ | $ | ||||||||||||
Total liabilities |
$ | $ | $ | $ | ||||||||||||
Fair value at December 31, 2021 |
||||||||||||||||
Total |
Level 1 |
Level 2 |
Level 3 |
|||||||||||||
Liabilities: |
||||||||||||||||
Derivative liability |
$ | $ | $ | $ | ||||||||||||
Total liabilities |
$ | $ | $ | $ | ||||||||||||
For the Six Months Ended June 30, |
||||||||
2022 |
2021 |
|||||||
Derivative liability: |
||||||||
Balance, beginning of period |
$ | $ | ||||||
(Gain) loss on fair value of derivative liability |
( |
) | ||||||
Change in fair value of derivative liability upon exercise of warrants |
( |
) | ||||||
Balance, end of period |
$ | $ | ||||||
Less than 1 year |
1 to 3 years |
3 to 5 years |
Greater than 5 years |
Total |
||||||||||||||||
Accounts payable and accrued liabilities |
$ | $ | $ | $ | — | $ | ||||||||||||||
Convertible notes, notes payable and accrued interest |
— | — | ||||||||||||||||||
Contingent consideration payable |
— | — | ||||||||||||||||||
Construction finance liability |
— | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total |
$ | $ | $ | $ | — | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
• | THC Cannabis – Production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers, ancillary services supporting wholesale operations, and retail sales direct to end consumers ; and |
• | CBD Wellness – Pure Ratios which encompasses the production and sale of CBD products to third-party customers . |
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Net Revenues |
||||||||||||||||
THC Cannabis |
$ | $ | $ | $ | ||||||||||||
CBD Wellness |
||||||||||||||||
Corporate |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Net Revenues |
||||||||||||||||
Depreciation and Amortization |
||||||||||||||||
THC Cannabis |
||||||||||||||||
CBD Wellness |
||||||||||||||||
Corporate |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Depreciation and Amortization |
||||||||||||||||
Net (Income) Loss |
||||||||||||||||
THC Cannabis |
||||||||||||||||
CBD Wellness |
( |
) | ( |
) | ||||||||||||
Corporate |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Net Loss |
$ | $ | $ | $ |
Assets |
June 30, 2022 |
December 31, 2021 |
||||||
THC Cannabis |
$ | $ | ||||||
CBD Wellness |
||||||||
Corporate |
||||||||
|
|
|
|
|||||
Total Assets |
$ |
$ |
June 30, 2022 |
June 30, 2021 |
|||||||
Changes in operating assets and liabilities |
||||||||
Accounts receivable and other receivables |
$ | ( |
) | $ | ( |
) | ||
Inventory |
( |
) | ( |
) | ||||
Prepaid expenses |
( |
) | ||||||
Deposits |
( |
) | ||||||
Accounts payable and accrued liabilities |
||||||||
Taxes payable |
||||||||
|
|
|
|
|||||
$ | $ | ( |
) | |||||
|
|
|
|
June 30, 2022 |
June 30, 2021 |
|||||||
Exchange of convertible debt to equity |
$ | $ | ||||||
|
|
|
|
|||||
Change in right-of-use |
$ | $ | ||||||
|
|
|
|
|||||
Issuance of equity to pay contingent consideration |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Issuance of debt to pay contingent consideration |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Equity portion of warrants recorded through derivative liability |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Issuance of equity for NECC pursuant to acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Property, plant, and equipment acquired through NECC acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Issuance of notes payable through NECC acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Inventory acquired through NECC acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Issuance of equity for Island pursuant to acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Issuance of warrants for Island pursuant to acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Property and equipment acquired through Island acquisition |
$ | $ | ||||||
|
|
|
|
|||||
ROU asset and lease liability acquired through Island acquisition |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Note payable acquired through Island acquisition |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Issuance of notes payable through Island acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Inventory acquired through Island acquisition |
$ | $ | ||||||
|
|
|
|
|||||
Issuance of debt to acquire property and equipment |
$ | $ | ||||||
|
|
|
|
|||||
Inventory acquired through issuance of note payable |
$ | $ | ||||||
|
|
|
|
|||||
Cancellation of ROU asset and lease liability |
$ |
$ |
||||||
|
|
|
|
|||||
Note payable issued to satisfy accrued expenses |
$ |
$ |
||||||
|
|
|
|
• | Cash paid for interest for the six months ended June 30, 2022 and 2021 was $ |
• | Cash paid for income taxes for the six months ended June 30, 2022 and 2021 was $ |
For the Three Months Ended June |
For the Six Months Ended June 30, |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Net loss before income taxes |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Income tax expense |
( |
) | ( |
) | ( |
) | ( |
) |
For the Three Months Ended June 30, |
Change |
|||||||||||||||
2022 |
2021 |
$ |
% |
|||||||||||||
Revenue from Sale of Goods |
$ | 25,488 | $ | 24,452 | $ | 1,036 | 4 | % | ||||||||
Real Estate Income |
2,951 | 2,669 | 282 | 11 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Revenues |
28,439 | 27,121 | 1,318 | 5 | % | |||||||||||
Cost of Goods Sold |
(16,123 | ) | (10,816 | ) | (5,307 | ) | 49 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross profit |
12,316 | 16,305 | (3,989 | ) | 24 | % | ||||||||||
Total Operating Expense |
16,415 | 15,637 | 778 | 5 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (Loss) from Operations |
(4,099 | ) | 668 | (4,767 | ) | 714 | % | |||||||||
Total Other income (expense), net |
595 | (3,535 | ) | 4,130 | 117 | % | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss Before Income Taxes |
(3,504 | ) | (2,867 | ) | (637 | ) | 22 | % | ||||||||
Income Tax Expense |
(3,042 | ) | (3,351 | ) | 309 | 9 | % | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss from Continuing Operations |
(6,546 | ) | (6,218 | ) | (328 | ) | 5 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss |
$ | (6,546 | ) | $ | (6,218 | ) | $ | (328 | ) | 5 | % | |||||
|
|
|
|
|
|
|
|
For the Six Months Ended June 30, |
Change |
|||||||||||||||
2022 |
2021 |
$ |
% |
|||||||||||||
Revenue from Sale of Goods |
$ | 48,571 | $ | 44,532 | $ | 4,039 | 9 | % | ||||||||
Real Estate Income |
5,916 | 5,559 | 357 | 6 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Revenues |
54,487 | 50,091 | 4,396 | 9 | % | |||||||||||
Cost of Goods Sold |
(28,717 | ) | (19,941 | ) | (8,776 | ) | 44 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross profit |
25,770 | 30,150 | (4,380 | ) | 15 | % | ||||||||||
Total Operating Expense |
31,110 | 29,129 | 1,981 | 7 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Income (Loss) from Operations |
(5,340 | ) | 1,021 | (6,361 | ) | 623 | % | |||||||||
Total Other income (expense), net |
(620 | ) | (12,319 | ) | 11,699 | 95 | % | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss Before Income Taxes |
(5,960 | ) | (11,298 | ) | 5,338 | 47 | % | |||||||||
Income Tax Expense |
(6,480 | ) | (6,004 | ) | (476 | ) | 8 | % | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss from Continuing Operations |
(12,440 | ) | (17,302 | ) | 4,862 | 28 | % | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net Loss |
$ | (12,440 | ) | $ | (17,302 | ) | $ | 4,862 | 28 | % | ||||||
|
|
|
|
|
|
|
|
Six months ended June 30, |
2022 |
2021 |
||||||
Net loss (GAAP) |
$ | (12,440 | ) | $ | (17,302 | ) | ||
Interest income |
(2 | ) | (11 | ) | ||||
Interest expense |
9,274 | 5,362 | ||||||
Amortization of loan discount upon conversion of debt to equity |
— | 2,915 | ||||||
Income tax expense |
6,480 | 6,004 | ||||||
Depreciation and amortization |
4,689 | 2,166 | ||||||
Accretion of liability expense |
7,400 | — | ||||||
Equity based compensation |
1,428 | 5,375 | ||||||
Change in contingent consideration payable |
(2,393 | ) | — | |||||
Change in value of derivative liability |
(3,074 | ) | 2,843 | |||||
Acquisition, transaction, and other one-time costs |
3,010 | 3,054 | ||||||
Non-cash inventory adjustment |
1,600 | — | ||||||
Non-cash lease expense |
2,213 | 1,765 | ||||||
Loss on lease termination |
— | 1,210 | ||||||
|
|
|
|
|||||
Adjusted EBITDA (Non-GAAP) |
$ | 18,185 | $ | 13,381 | ||||
|
|
|
|
Three months ended June 30, |
2022 |
2021 |
||||||
Net loss (GAAP) |
$ |
(6,546 |
) |
$ |
(6,218 |
) | ||
Interest income |
— |
(8 |
) | |||||
Interest expense |
5,047 |
2,901 |
||||||
Amortization of loan discount upon conversion of debt to equity |
— |
— |
||||||
Income tax expense |
3,042 |
3,351 |
||||||
Depreciation and amortization |
2,894 |
1,120 |
||||||
Accretion of liability expense |
3,694 |
— |
||||||
Equity based compensation |
390 |
2,979 |
||||||
Change in contingent consideration payable |
(2,393 |
) |
— |
|||||
Change in value of derivative liability |
(1,774 |
) |
311 |
|||||
Acquisition, transaction, and other one-time costs |
2,119 |
1,558 |
||||||
Non-cash inventory adjustment |
1,600 |
— |
||||||
Non-cash lease expense |
1,088 |
1,153 |
||||||
Loss on lease termination |
— |
331 |
||||||
|
|
|
|
|||||
Adjusted EBITDA (Non-GAAP) |
$ |
9,161 |
$ |
7,478 |
||||
|
|
|
|
• | Interest income and expense |
• | Current income tax expense |
• | Non-cash depreciation and amortization expense |
• | Accretion expense related to a periodic update of the present value of a liability |
• | Equity based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy |
• | Legal settlements |
• | Non-cash change in fair value of derivative liability |
• | Acquisition, transaction, and other expenses (income), which vary significantly by transaction and are excluded to evaluate ongoing operating results |
• | We did not have sufficient accounting staff resources to timely perform closing and audit-related procedures. |
• | We did not have effective controls over the review procedures for balance sheet account reconciliations and manual journal entries. |
• | We did not have documented evidence of review procedures and did not have sufficient segregation of duties within our accounting function. |
• | The Company will assess sufficient resources, both in accounting staff and related technology, needed to timely perform closing and audit-related procedures and align identified resources. |
• | The Company will assess controls needed to effectively review procedures for balance sheet account reconciliations and manual journal entries and implement identified controls. |
• | The Company will assess review procedures to have sufficient segregation of duties within our accounting function, then standardize and document such procedures for evidence of review. |
Exhibit Number |
Exhibit Description |
Form |
Filing Date |
Exhibit Number |
Filed Herewith | |||||
31.1 | Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act | x | ||||||||
31.2 | Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act | x | ||||||||
32.1 | Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) Under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code * | x | ||||||||
101.INS | Inline XBRL Instance Document | |||||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
+ | Indicates management contract or compensatory plan. |
* | This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
4FRONT VENTURES CORP. | ||||||
Date: August 15, 2022 |
By: |
/s/ Leo Gontmakher | ||||
Leo Gontmakher | ||||||
Chief Executive Officer and Director | ||||||
(Principal Executive Officer) | ||||||
Date: August 15, 2022 |
By: |
/s/ Keith Adams | ||||
Keith Adams | ||||||
Chief Financial Officer | ||||||
(Principal Financial Officer) |
Exhibit 31.1
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Leonid Gontmakher, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of 4Front Ventures Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: August 15, 2022 | /s/ Leonid Gontmakher | |||||
Leonid Gontmakher, Chief Executive Officer | ||||||
(principal executive officer) |
Exhibit 31.2
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Keith Adams, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of 4Front Ventures Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: August 15, 2022 | /s/ Keith Adams | |||||
Keith Adams, Chief Financial Officer | ||||||
(principal financial and accounting officer) |
Exhibit 32.1
Certifications of Chief Executive Officer and Interim Chief Financial Officer
pursuant to
18 U.S.C. Section 1350,
as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Leonid Gontmakher, Chief Executive Officer (principal executive officer) of 4Front Ventures Corp. (the Company), and Peter Rennard, Interim Chief Financial Officer (principal financial and accounting officer) of the Company, each hereby certifies that, to the best of his knowledge:
1) | The Companys Quarterly Report on Form 10-Q for three months ended March 31, 2022, to which this certification is attached as Exhibit 32.1 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: August 15, 2022
/s/ Leonid Gontmakher |
Leonid Gontmakher Chief Executive
Officer (principal executive officer) |
/s/ Keith Adams |
Keith Adams Chief Financial Officer (principal financial and accounting officer) |
The foregoing certifications are being furnished pursuant to 18 U.S.C. Section 1350. They are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Company, regardless of any general incorporation language in such filing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 4Front Ventures Announces Issuance of Securities to Consultants, Directors, and Officers
- Form 8.5 (EPT/RI) - musicMagpie Plc
- Municipality Finance issues a GBP 50 million tap under its MTN programme
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!